LANTHEUS HOLDINGS, INC. (NASDAQ:LNTH) Files An 8-K Entry into a Material Definitive Agreement
Item1.01
| Entry into a Material Definitive Agreement |
Underwriting Agreement
On June14, 2017, Lantheus Holdings, Inc. (the Company)
entered into an underwriting agreement (the Underwriting
Agreement) with the selling stockholders listed on Schedule
II thereto (the Selling Stockholders) and Credit Suisse
Securities (USA) LLC and Cantor Fitzgerald Co., as the
underwriters (the Underwriters), relating to the
underwritten offering of 3,000,000 shares (the Shares) of
the Companys common stock, par value $0.01 per share (the
Offering). All of the Shares are being sold by the Selling
Stockholders. The Underwriters have agreed to purchase the Shares
from the Selling Stockholders to the Underwriting Agreement at a
price of $14.87 per share.
The Offering is being made only by means of a prospectus. A shelf
registration statement (including a prospectus) relating to the
offering of common stock was filed with the Securities and
Exchange Commission (the SEC) on December12, 2016, and
became effective on January4, 2017 (Registration No.333-215055)
(the Registration Statement). Prospectus supplements
relating to the Offering have been filed with the SEC. The
closing of the Offering is expected to take place on June20,
2017, subject to the satisfaction of customary closing
conditions. A copy of the Underwriting Agreement is filed as
Exhibit 1.1 to this Current Report on Form 8-K.
| Item8.01 | Other Events |
Ropes Gray LLP, counsel to the Company, has issued an opinion to
the Company, dated June16, 2017, regarding the Shares to be sold
in the Offering. A copy of the opinion is filed as Exhibit 5.1 to
this Current Report on Form 8-K. Certain information relating to
Part II, Item14 Other Expenses of Issuance and Distribution of
the Registration Statement is filed as Exhibit 99.1 to this
Current Report on Form 8-K.
| Item9.01 | Financial Statements and Exhibits |
| (d) | Exhibits |
| Exhibit Number | Description | |
| 1.1 |
Underwriting Agreement, dated June 14, 2017, by and among the Company, the Selling Stockholders and the Underwriters. |
|
| 5.1 | Opinion of Ropes Gray LLP. | |
| 23.1 | Consent of Ropes Gray LLP (included in Exhibit 5.1 above). | |
| 99.1 |
Information relating to Part II, Item 14 Other Expenses of Issuance and Distribution of the Registration Statement. |
About LANTHEUS HOLDINGS, INC. (NASDAQ:LNTH)
Lantheus Holdings, Inc. develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities. The Company’s Contrast agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging or magnetic resonance imaging (MRI), which are used by physicians to progress the clarity of the diagnostic image. Radiopharmaceuticals are radioactive pharmaceuticals used by clinicians to perform nuclear imaging procedures. The Company’s imaging agents include contrast agents and medical radiopharmaceuticals (including technetium generators), including DEFINITY, TechneLite, Xenon Xe 133 Gas (Xenon), Cardiolite and Neurolite.
